Clinical trial NCT02860520: Clinical Implication of Retinitis Pigmentosa Molecular Diagnostic Using High Throughput Sequencing.
Official title: Clinical Implication of the Molecular Diagnostic Retinitis Pigmentosa Molecular Diagnostic Using High Throughput Sequencing (RP-SEQ-HD)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Retinitis Pigmentosa
Keywords: Retinitis pigmentosa:
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2016-08-09
Enrollment: 500
Sex: ALL
Minimum age (years): 2
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with an RP and/or having a family history of RP

Brief summary: The retinitis pigmentosa (RP) are genetic conditions that cause retinal degeneration leading to severe low vision and is the leading cause of consultation in reference centers dedicated to the ophthalmic genetics. These rare diseases are characterized by a triple heterogeneity (clinical, genetic and molecular), which made them unreachable by traditional molecular diagnostic sequencing technology by the large number of genes to be tested (\> 190).

The advent of high-throughput sequencing (NGS) and targeted capture has opened unexpected possibilities of investigation and ultimately to improve the care of patients. This project aims to study the genetic and molecular epidemiology of an interregional french (grand EST) cohort of patients. Patients receive a detailed retinal phenotype (visual acuity, visual field, photographs of the fundus and ERG). Their DNA will be analyzed by NGS targets the 190 known genes (https://sph.uth.edu/retnet/).

This research will provide a molecular epidemiological cohort study compared to prior publications on the frequency of genes involved. The benefit for patients is important to: establish a mode of transmission of the disease and optimize genetic counseling (currently very empirical); establish phenotype-genotype correlations in the French population (very few studies to date) and from the data of international literature; identify patients likely to be included in future therapeutic protocols of research; identify patients with significant potential for future projects to identify new genes.

The primary purpose of the protocol is to use high throughput sequencing to identify pathogenic variants in genes involved in RP.

The secondary purposes will be the following:

* Determining the diagnostic yield
* Study the genotype-phenotype correlation.

The secondary purposes will be the following:

* Determining the diagnostic yield
* Study the genotype-phenotype correlation


Eligibility criteria: Inclusion Criteria:

* Subject of both sex, aged at least 2 years, being diagnosed with an RP, and/or having a family history of RP
* Informed about the results of the preliminary medical visit, or which (s) holder (s) parental authority or the guardian / curator has (have) was (been) informed
* Informed consent signed
* Affiliation to the French health system

Exclusion Criteria:

* The patient does not want to participate to the protocol
* Intercurrent diseases do not allow the practice of tests provided for this protocol
* Phenocopy
* Subject excluded or being excluded by another protocol
* Subject in emergency case
* Subject under judicial protection

Primary outcomes:
measure: Number of patients with a deleterious mutation
timeFrame: 18 months
Secondary outcomes:
measure: Percentage of positive diagnostic
timeFrame: 18 months
measure: Number of gene with a genotype-phenotype correlation
timeFrame: 18 months
Other outcomes:
Locations:
city: Dijon
country: France
facility: Service d'Ophtalmologie CHU Hôpital Général
city: Reims
country: France
facility: Service d'Ophtalmologie, Hôpital Robert Debré, CHR
city: Strasbourg
country: France
facility: Affections Rares en Génétique Ophtalmologique (CARGO) Hôpital Civil, Hôpitaux Universitaires de Strasbourg
city: Vandoeuvre Les Nancy
country: France
facility: Service d'Ophtalmologie, CHU BRABOIS
Study officials:
affiliation: Hôpitaux Universitaires de Strasbourg
name: Hélène DOLLFUS, MD
role: PRINCIPAL_INVESTIGATOR
References: